{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:46Z","timestamp":1794047386436,"version":"4.8.0"},"reference-count":24,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Novel treatment strategies are needed to improve cure for all children with acute lymphoblastic leukemia (ALL). To this end, we investigated the therapeutic potential of clofarabine in primary ALL in trial CoALL 08-09 (clinicaltrials gov. identifier: NCT01228331). The primary study objective was the minimal residual disease (MRD)- based comparative assessment of cytotoxic efficacies of clofarabine 5x40 mg\/m2 versus high-dose cytarabine (HIDAC) 4x3g\/m2, both in combination with PEG-ASP 2,500 IU\/m2 as randomized intervention in early consolidation. The secondary objective was an outcome analysis focused on treatment arm dependence and MRD after randomized intervention. In B-cell precursor (BCP)-ALL, eradication of MRD was more profound after clofarabine compared to cytarabine, with 93 versus 79 of 143 randomized patients per arm reaching MRD-negativity (c2 test P=0.03, leftsided P [Fisher\u2019s exact test]=0.04). MRD status of BCP-ALL after randomized intervention maintained its prognostic relevance, with a significant impact on event-free survival (EFS) and relapse rate. However, no difference in outcome regarding EFS and overall survival (OS) between randomized courses was observed (5-year EFS: clofarabine 85.7, SE=4.1 vs. HIDAC 84.8, SE=4.7 [P=0.96]; OS: 95.7, SE=1.9 vs. 92.2, SE=3.2 [P=0.59]), independent of covariates or overall risk strata. Severe toxicities between randomized and subsequent treatment elements were also without significant difference. In conclusion, clofarabine\/PEG-ASP is effective and safe, but greater cytotoxic efficacy of clofarabine compared to HIDAC did not translate into improved outcomes indicating a lack of surrogacy of post-intervention MRD at the trial level as opposed to the patient level, which hampers a broader implementation of this regimen in the frontline treatment of ALL.<\/jats:p>","DOI":"10.3324\/haematol.2021.279357","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T03:19:11Z","timestamp":1628133551000},"page":"1026-1033","source":"Crossref","is-referenced-by-count":8,"title":["Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group"],"prefix":"10.3324","volume":"107","author":[{"given":"Gabriele","family":"Escherich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Zur Stadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Borkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Dilloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Feuchtinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Imschweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Jorch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnulf","family":"Pekrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Spohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A","family":"Horstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"35218","unstructured":"Xie KC, Plunkett W.. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluorobeta- D-arabinofuranosyl) adenine. Cancer Res. 1996; 56(13):3030-3037."},{"key":"35219","doi-asserted-by":"crossref","unstructured":"Jeha S, Gandhi V, Chan KW. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukaemia. Blood. 2004; 103(3):784-789.","DOI":"10.1182\/blood-2003-06-2122"},{"key":"35220","doi-asserted-by":"crossref","unstructured":"Huang M, Inukai T, Miyake K. Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression. Cancer Med. 2018; 7(4):1297-1316.","DOI":"10.1002\/cam4.1323"},{"key":"35221","doi-asserted-by":"crossref","unstructured":"Huguet F, Leguay T, Raffoux E. Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup. Leuk Lymphoma. 2015; 56(4):847-857.","DOI":"10.3109\/10428194.2014.887708"},{"key":"35222","doi-asserted-by":"crossref","unstructured":"Wang H, Jones AK, Dvorak CC. Population pharmacokinetics of cofarabine as part of pretransplantation conditioning in pediatric subjects before hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019; 25(8):1603-1610.","DOI":"10.1016\/j.bbmt.2019.04.017"},{"key":"35223","doi-asserted-by":"crossref","unstructured":"Hochberg J, Zahler S, Geyer MB. The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia. Bone Marrow Transplant. 2019; 54(2):226-235.","DOI":"10.1038\/s41409-018-0247-9"},{"key":"35224","doi-asserted-by":"crossref","unstructured":"Salzer WL, Burke MJ, Devidas M. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: a report from the Children's Oncology Group study AALL1131. Cancer. 2018; 124(6):1150-1159.","DOI":"10.1002\/cncr.31099"},{"key":"35225","doi-asserted-by":"crossref","unstructured":"Escherich G, zur Stadt U, Zimmermann M, Horstmann MA. CoALL study group. Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial. Br J Haematol. 2013; 163(2):240-247.","DOI":"10.1111\/bjh.12520"},{"key":"35226","doi-asserted-by":"crossref","unstructured":"Schramm F, Zimmermann M, Jorch N. Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09. Leuk Lymphoma. 2019; 60(1):60-68.","DOI":"10.1080\/10428194.2018.1473575"},{"key":"35227","doi-asserted-by":"crossref","unstructured":"Van der Velden VHJ, Cazzaniga G, Schrauder A. European Study Group on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007; 21(4):604-611.","DOI":"10.1038\/sj.leu.2404586"},{"key":"35228","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P.. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53(282):457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"35229","doi-asserted-by":"crossref","unstructured":"Aalen OO. 1. The statistical analysis of failure time data (2nd edn). Kalbfleisch JD, Prentice LR, Wiley-Interscience, Hoboken, New Jersey, 2002. Statistics in Medicine. 2004; 23(21):3397-3398.","DOI":"10.1002\/sim.1699"},{"key":"35230","doi-asserted-by":"crossref","unstructured":"Gray RJ. A Class of K-Sample Tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics. 1988; 16(3):1141-1154.","DOI":"10.1214\/aos\/1176350951"},{"key":"35231","doi-asserted-by":"crossref","unstructured":"Margolin BH. Test for Trend in Proportions. 1988; vol. 9:334-336.","DOI":"10.1038\/336334a0"},{"key":"35232","doi-asserted-by":"crossref","unstructured":"Borowitz MJ, Devidas M, Hunger SP. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008; 111(12):5477-5485.","DOI":"10.1182\/blood-2008-01-132837"},{"key":"35233","doi-asserted-by":"crossref","unstructured":"Br\u00fcggemann M, Kotrova M.. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Adv. 2017; 1(25):2456-2466.","DOI":"10.1182\/bloodadvances.2017009845"},{"key":"35234","doi-asserted-by":"crossref","unstructured":"Galimberti S, Devidas M, Lucenti A. Validation of minimal residual disease as surrogate endpoint for event-free survival in childhood acute lymphoblastic leukemia. JNCI Cancer Spectr. 2018; 2(4):pky069.","DOI":"10.1093\/jncics\/pky069"},{"key":"35235","doi-asserted-by":"crossref","unstructured":"M\u00f6ricke A, Zimmermann M, Valsecchi MG. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016; 127(17):2101-2112.","DOI":"10.1182\/blood-2015-09-670729"},{"key":"35236","doi-asserted-by":"crossref","unstructured":"Borowitz MJ, Wood BL, Devidas M. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. Blood. 2015; 126(8):964-971.","DOI":"10.1182\/blood-2015-03-633685"},{"key":"35237","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Gandhi V, Kozuch V. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003; 21(6):1167-1173.","DOI":"10.1200\/JCO.2003.04.031"},{"key":"35238","doi-asserted-by":"crossref","unstructured":"Locatelli F, Whitlock JA, Peters C. Blinatumomab versus historical standard therapy in pediatric patients with relapsed\/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia. 2020; 34(9):2473-2478.","DOI":"10.1038\/s41375-020-0770-8"},{"key":"35239","doi-asserted-by":"crossref","unstructured":"Curren E, Stock W.. Taking a \u201cBiTE out of ALL\u201d: blinatumomab approval for MRDpositive ALL. Blood. 2019; 133(16):1715-1719.","DOI":"10.1182\/blood-2018-12-852376"},{"key":"35240","doi-asserted-by":"crossref","unstructured":"Armenian S, Bhatia S.. Predicting and preventing anthracycline-related cardiotoxicity. Am Soc Clin Oncol Educ Book. 2018; 38:3-12.","DOI":"10.1200\/EDBK_100015"},{"key":"35241","doi-asserted-by":"crossref","unstructured":"Bhojwani D, Sabin ND, Pei D. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014; 32(9):949-959.","DOI":"10.1200\/JCO.2013.53.0808"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279357\/74377","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279357\/74378","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10360\/73599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:00:09Z","timestamp":1794045609000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.279357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.279357","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,5]]}}}